MedPath

A Bilateral Dispensing Comparison of Comfilcon A Over Senofilcon C Contact Lenses

Not Applicable
Completed
Conditions
Astigmatism Bilateral
Interventions
Device: Comfilcon A (test)
Device: Senofilcon C (control)
Registration Number
NCT03684928
Lead Sponsor
Coopervision, Inc.
Brief Summary

The aim of this study is to evaluate the subjective acceptance of Comfilcon A contact lenses when worn on a daily wear modality over one month.

Detailed Description

This study is a 30-subjects prospective, double-masked (investigator and participant), bilateral, randomized, one month cross-over dispensing study comparing subject acceptance of Comfilcon A against Senofilcon A contact lenses.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

  1. Is at least 17 years of age and has full legal capacity to volunteer;
  2. Has had a self-reported oculo-visual examination in the last two years.
  3. Has read and signed an information consent letter;
  4. Is willing and able to follow instructions and maintain the appointment schedule;
  5. Is an adapted soft contact lens wearer, who currently wears contact lenses for a minimum 3 days/week and 8 hours/day AND who anticipates no difficulty wearing CLs for 6 days/week, 10 hours /day.
  6. Is willing to wear contact lens in both eyes for the duration of the study;
  7. Has a minimum astigmatism of - 0.75, determined by refraction;
  8. Can be fit with the two study contact lens types in the powers available;
  9. Has a distance visual acuity of 0.20 logMAR (approx 20/30) or better, determined by refraction;
  10. Can achieve a distance visual acuity of 0.20 logMAR (approx 20/30) or better in each eye with the study contact lenses.
  11. Has clear corneas and no active* ocular disease;
Exclusion Criteria

A person will be excluded from the study if he/she:

  1. Is participating in any concurrent clinical trial;
  2. Has any known active* ocular disease and/or infection;
  3. Has a systemic condition that in the opinion of the investigator may affect a study measure;
  4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study measure;
  5. Has known sensitivity to fluorescein dye or products to be used in the study;
  6. Appears to have any active* ocular pathology, ocular anomaly or severe insufficiency of lacrimal secretion (severe dry eye) that would affect the wearing of contact lenses;
  7. Is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
  8. Is aphakic;
  9. Has undergone refractive error surgery;
  10. Has participated in the previous QUENA study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Senofilcon C (control)Senofilcon C (control)Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
Comfilcon A (test)Comfilcon A (test)Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
Comfilcon A (test)Senofilcon C (control)Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
Senofilcon C (control)Comfilcon A (test)Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
Primary Outcome Measures
NameTimeMethod
Ease of Insertion(Handling)1 month

Subjective ratings of ease of insertion for each pair of lenses (scale: 0-10; 0= Very difficult,10 = Very easy)

Ease of Insertion (Handling)2 weeks

Subjective ratings of ease of insertion for each pair of lenses (scale: 0-10; 0= Very difficult,10 = Very easy)

Secondary Outcome Measures
NameTimeMethod
Rotational Recovery After Lens Mislocation1 month

Lens relocation after 10 blinks, after 30º rotation mislocation.

Trial Locations

Locations (1)

University Of Waterloo

🇨🇦

Waterloo, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath